ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

Yu, Yaya; Xiao, Zhenzhen; Lei, Chenjing; Ma, Changju; Ding, Lina; Tang, Qing; He, Yihan; Chen, Yadong; Chang, Xuesong; Zhu, Yanjuan*; Zhang, Haibo*广东省人民医院; 广州中医药大学
BMC CANCER2023-8-8DOI: 10.1186/s12885-023-11243-0
5阅读
引用收藏
分享

摘要

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation often obtain de novo resistance or develop secondary resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), which restricts the clinical benefit for the patients. The activation of phosphatidylinositol 3-kinase (PI3K)/AKT signal pathway is one of the most important mechanisms for the EGFR-TKIs resistance beyond T790M mutation. There are currently no drugs simultaneously targeting EGFR and PI3K signal pathways, and combination of these two pathway inhibitors may be a possible strategy to reverse theses resistances. To test whether this combinational strategy works, we investigated the therapeutic effects and mechanisms of combining BYL719, a PI3K & alpha; inhibitor, with gefitinib, an EGFR-TKI inhibitor in EGFR-TKIs resistance NSCLC models induced by PI3K/AKT activation. Our results demonstrated that PIK3CA mutated cells showed increased growth rate and less sensitive or even resistant to gefitinib, associated with increased PI3K/AKT expression. The combination of BYL719 and gefitinib resulted in synergistic effect compared with the single agents alone in EGFR-mutated NSCLC cells with PI3K/AKT activation. The inhibition of AKT phosphorylation by BYL719 increased the antitumor efficacy of gefitinib in these cell lines. Moreover, the combined effect and mechanism of gefitinib and BYL719 were also confirmed in the NSCLC cells and patient-derived organoids under 3D culture condition, as well as in vivo. Taken together, the data indicate that PIK3CA mutation induces more aggressive growth and gefitinib resistance in NSCLC cells, and the combination treatment with gefitinib and BYL719 is a promising therapeutic approach to overcoming EGFR-TKIs resistance induced by PI3K/AKT activation.

学科与关键词

关键词
Non-small cell lung cancerEpidermal growth factor receptorPIK3CAPhosphatidylinositol 3-kinaseGefitinibBYL719
相关
加载中…
  • TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer
    Shuai, Shuai*; Liao, Xueyang; Wang, Haixia; Liu, Lusha; Mei, Shiqi; Cao, Jiaxin; Wang, Senming*Cancer Science, 2021, 112(10): 4139-4150.被引 5
  • Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation
    Ma, Changju; Zhang, Xin; Mo, Xiaomin; Yu, Yaya; Xiao, Zhenzhen; Wu, Jingjing; Ding, Lina; Lei, Chenjing; Zhu, Yanjuan*; Zhang, Haibo*PHYTOMEDICINE, 2024, 125: 155351.
  • An Activatable Nano-Prodrug for Treating Tyrosine-Kinase-Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging
    Xie, Xin; Zhan, Chenyue; Wang, Jie; Zeng, Fang*; Wu, Shuizhu*Small, 2020, 16(38): 2003451.被引 22
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-08-08
卷期
第 23 卷, 第 1 期
页码
732
DOI
10.1186/s12885-023-11243-0
语言
ENGLISH
成果收录
SCIE
资助标注
Guangzhou Municipal Science and Technology Bureau, China

作者

  • Y

    Yu, Yaya (第一作者)

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • X

    Xiao, Zhenzhen

    guangdong prov hosp · 2 · guangzhou univ chinese med

查看全部 11 位作者收起作者
  • L

    Lei, Chenjing

    2 · guangzhou univ chinese med

  • M

    Ma, Changju

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • D

    Ding, Lina

    2 · guangzhou univ chinese med

  • T

    Tang, Qing

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • H

    He, Yihan

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • C

    Chen, Yadong

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • C

    Chang, Xuesong

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • Z

    Zhu, Yanjuan (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • Z

    Zhang, Haibo (通讯)

    guangdong prov hosp · 2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417